Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19.Cancer Vaccine Analytical Characterization.Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells.CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology.CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs).Antibody-Coupled T Cell Receptor (ACTR) Platform.NR4A Knock Out CAR-T Cell Development with CRISPR Technology.TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology.Nanoparticle Tiny Tech for Programming T Cells.High-throughput Screening for T Cell Activity Modulator Discovery.Modular CAR-T Cell Generation with AAV-Cpf1.Organoid-induced Differentiation of Conventional T Cells from hPSCs.CellRapeutics™ Antibody-TCR (AbTCR) Technology.CellRapeutics™ Anti-HIV CAR Cell Therapy Development.TCR-Like CAR Construction and Evaluation Service.TCR-Like Antibody Affinity Characterization.MHC/Peptide Complex Production for TCR-Like Antibody Discovery.One-stop Cytokine Release Syndrome (CRS) Management Solutions.iPSC-derived CAR-NK Therapy Development.TCR Biomarker Identification & Selection.Replication-Competent Virus Testing Service.
0 kommentar(er)
